Boehringer Ingelheim and GoodRx, a prescription savings platform, have announced a patient affordability initiative to provide citrate-free Adalimumab-adbm, Boehringer’s biosimilar to Humira (adalimumab), at a low cash price available exclusively on GoodRx. This program aims to address access and affordability in one of the largest therapeutic categories with a high cost burden for patients. Adalimumab-adbm is an FDA-approved interchangeable biosimilar to Humira. The citrate-free, ...